InsiderTrades.com logo
Michel Detheux net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michel Detheux Biography and Net Worth

CEO of iTeos Therapeutics
Michel has served as our Chief Executive Officer and a director since our inception. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012. Prior to that, Michel worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).

Michel holds a degree in biochemistry degree and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School.

What is Michel Detheux's net worth?

The estimated net worth of Michel Detheux is at least $1.38 million as of June 9th, 2025. Dr. Detheux owns 135,903 shares of iTeos Therapeutics stock worth more than $1,379,415 as of December 4th. This net worth approximation does not reflect any other investments that Dr. Detheux may own. Additionally, Dr. Detheux receives a salary of $1,040,000.00 as CEO at iTeos Therapeutics. Learn More about Michel Detheux's net worth.

How old is Michel Detheux?

Dr. Detheux is currently 57 years old. There are 4 older executives and no younger executives at iTeos Therapeutics. Learn More on Michel Detheux's age.

What is Michel Detheux's salary?

As the CEO of iTeos Therapeutics, Inc., Dr. Detheux earns $1,040,000.00 per year. Learn More on Michel Detheux's salary.

How do I contact Michel Detheux?

The corporate mailing address for Dr. Detheux and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Michel Detheux's contact information.

Has Michel Detheux been buying or selling shares of iTeos Therapeutics?

Michel Detheux has not been actively trading shares of iTeos Therapeutics during the past quarter. Most recently, Michel Detheux sold 43,883 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a transaction totalling $439,707.66. Following the completion of the sale, the chief executive officer now directly owns 153,903 shares of the company's stock, valued at $1,542,108.06. Learn More on Michel Detheux's trading history.

Who are iTeos Therapeutics' active insiders?

iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.

Are insiders buying or selling shares of iTeos Therapeutics?

During the last year, insiders at the sold shares 11 times. They sold a total of 1,939,307 shares worth more than $16,202,115.73. The most recent insider tranaction occured on June, 10th when CEO Michel Detheux sold 43,883 shares worth more than $439,707.66. Insiders at iTeos Therapeutics own 14.2% of the company. Learn More about insider trades at iTeos Therapeutics.

Information on this page was last updated on 6/10/2025.

Michel Detheux Insider Trading History at iTeos Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2025Sell43,883$10.02$439,707.66153,903View SEC Filing Icon  
6/9/2025Sell8,400$10.03$84,252.00135,903View SEC Filing Icon  
6/9/2025Sell43,882$10.03$440,136.46153,903View SEC Filing Icon  
6/6/2025Sell8,400$10.21$85,764.00135,903View SEC Filing Icon  
6/6/2025Sell43,882$10.21$448,035.22135,903View SEC Filing Icon  
6/4/2025Sell8,400$10.10$84,840.00135,903View SEC Filing Icon  
6/4/2025Sell43,883$10.10$443,218.30135,903View SEC Filing Icon  
4/18/2022Sell11,500$31.87$366,505.0026,263View SEC Filing Icon  
3/22/2022Sell18,437$34.17$629,992.29View SEC Filing Icon  
2/23/2022Sell14,500$34.34$497,930.00View SEC Filing Icon  
1/25/2022Sell14,500$35.68$517,360.00View SEC Filing Icon  
12/22/2021Sell16,163$45.03$727,819.89View SEC Filing Icon  
12/20/2021Sell9,111$43.94$400,337.34View SEC Filing Icon  
11/23/2021Sell14,500$36.08$523,160.00View SEC Filing Icon  
11/3/2021Sell6,085$28.89$175,795.65View SEC Filing Icon  
11/1/2021Sell81$28.00$2,268.00View SEC Filing Icon  
10/21/2021Sell196$28.00$5,488.00View SEC Filing Icon  
10/19/2021Sell201$28.00$5,628.00View SEC Filing Icon  
10/15/2021Sell1,635$28.01$45,796.35View SEC Filing Icon  
9/23/2021Sell5,322$28.16$149,867.52View SEC Filing Icon  
9/1/2021Sell8,684$28.30$245,757.20View SEC Filing Icon  
8/30/2021Sell2,322$28.01$65,039.22132,104View SEC Filing Icon  
8/27/2021Sell8,248$28.17$232,346.16View SEC Filing Icon  
8/25/2021Sell861$28.00$24,108.00View SEC Filing Icon  
8/23/2021Sell7,499$28.06$210,421.94141,438View SEC Filing Icon  
6/14/2021Sell29,000$28.50$826,500.00152,874View SEC Filing Icon  
See Full Table

Michel Detheux Buying and Selling Activity at iTeos Therapeutics

This chart shows Michel Detheux's buying and selling at iTeos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iTeos Therapeutics Company Overview

iTeos Therapeutics logo
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $10.15
Low: $10.15
High: $10.15

50 Day Range

MA: $10.14
Low: $10.09
High: $10.23

2 Week Range

Now: $10.15
Low: $4.80
High: $17.63

Volume

N/A

Average Volume

1,505,580 shs

Market Capitalization

$448.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31